Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation

Bone Marrow Transplantation volume 57, pages 131–133 (2022)Cite this article

Subjects

Access through your institution
Buy or subscribe

TO THE EDITOR:

Allogeneic hematopoietic cell transplant (HCT) is a potentially curative therapy for many high-risk hematologic malignancies and bone marrow failure syndromes but is limited by significant mortality. While advances in supportive care and further understanding of patient and disease prognostic factors have led to improvements in day 100 morbidity and mortality [1,2,3], continued improvement in longer-term survival is still needed. In order to better identify patients at high risk for 1-year mortality, we developed a risk assessment tool to determine if pre-and early post-transplant variables (occurring within the first 100 days) could better identify patients at high risk for subsequent mortality.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hahn T, McCarthy PL Jr, Hassebroek A, Bredeson C, Gajewski J, Hale G, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013;31:2437–49.

    Article  Google Scholar 

  2. Lee SJ, Klein J, Haagenson M, Baxter-Lowe AL, Confer D, Eapen M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4576–83.

    Article  CAS  Google Scholar 

  3. Sorror ML, Sandmaier BM, Storer BE, Franke G, Laport G, Chauncey T, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306:1874–83.

    Article  CAS  Google Scholar 

  4. Elsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51:1283–300.

    Article  CAS  Google Scholar 

  5. Michelis FV, Messner HA, Atenafu EG, McGillis L, Lambie A, Uhm J, et al. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2. Bone Marrow Transplant. 2015;50:1405–10.

    Article  CAS  Google Scholar 

  6. Armand P, Gibson CJ, Cutler C, Ho V, Koreth J, Alyea E, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120:905–13.

    Article  CAS  Google Scholar 

  7. Barba P, Martino R, Pérez-Simón JA, Fernandez-Aviles F, Castillo N, Pinana J, et al. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:66–72.

    Article  Google Scholar 

  8. Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone A, Valcarcel D, et al. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. J Clin Oncol. 2016;34:1864–71.

    Article  Google Scholar 

  9. Patel SS, Rybicki LA, Corrigan D, Bolwell B, Dean R, Liu H, et al. Prognostic factors for mortality among day +100 survivors after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018;24:1029–34.

    Article  Google Scholar 

  10. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman M, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878–87.

    Article  Google Scholar 

  11. Damiani D, Tiribelli M, Geromin A, Cerno M, Sperotto A, Toffoletti E, et al. Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia. Ann Hematol. 2012;91:1937–43.

    Article  Google Scholar 

  12. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA

    Pranay Hegde

  2. Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA

    Lisa Rybicki

  3. Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

    Sheila Serafino, Christina Ferraro, Matt Kalaycio, Ronald Sobecks, Aaron T. Gerds, Sharon Caroniti, Donna Corrigan, Kayla Giannetti, Jamie Elberson, Brittany Hodgeman, Jamie Starn, Jane Dabney, Linda McLellan, Navneet S. Majhail & Betty K. Hamilton

Authors
  1. Pranay Hegde
    View author publications

    Search author on:PubMed Google Scholar

  2. Lisa Rybicki
    View author publications

    Search author on:PubMed Google Scholar

  3. Sheila Serafino
    View author publications

    Search author on:PubMed Google Scholar

  4. Christina Ferraro
    View author publications

    Search author on:PubMed Google Scholar

  5. Matt Kalaycio
    View author publications

    Search author on:PubMed Google Scholar

  6. Ronald Sobecks
    View author publications

    Search author on:PubMed Google Scholar

  7. Aaron T. Gerds
    View author publications

    Search author on:PubMed Google Scholar

  8. Sharon Caroniti
    View author publications

    Search author on:PubMed Google Scholar

  9. Donna Corrigan
    View author publications

    Search author on:PubMed Google Scholar

  10. Kayla Giannetti
    View author publications

    Search author on:PubMed Google Scholar

  11. Jamie Elberson
    View author publications

    Search author on:PubMed Google Scholar

  12. Brittany Hodgeman
    View author publications

    Search author on:PubMed Google Scholar

  13. Jamie Starn
    View author publications

    Search author on:PubMed Google Scholar

  14. Jane Dabney
    View author publications

    Search author on:PubMed Google Scholar

  15. Linda McLellan
    View author publications

    Search author on:PubMed Google Scholar

  16. Navneet S. Majhail
    View author publications

    Search author on:PubMed Google Scholar

  17. Betty K. Hamilton
    View author publications

    Search author on:PubMed Google Scholar

Contributions

PH analyzed and interpreted data and wrote the manuscript. LR provided statistical support and critically reviewed the manuscript. SS, CF, MK, RS, ATG, SC, DC, KG, JE, BH, JS, JD, LM, and NSM contributed to the development of the scoring system, patient data collection, and critically reviewed the manuscript. BKH contributed to the development of the scoring system, designed the study, analyzed and interpreted data, and wrote and critically reviewed the manuscript. All authors approved the final manuscript.

Corresponding author

Correspondence to Betty K. Hamilton.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hegde, P., Rybicki, L., Serafino, S. et al. Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 57, 131–133 (2022). https://doi.org/10.1038/s41409-021-01491-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41409-021-01491-8

Search

Advanced search

Quick links